Plus   Neg

Dermira Inc. (DERM) Has Tumbled To A New Low After Phase 3 Study Fails

Dermira Inc. (DERM) announced Monday morning that olumacostat glasaretil did not meet the co-primary endpoints in its two Phase 3 studies.

Dermira has gapped open sharply lower this morning and is now down 15.68 at $9.48 on the highest volume of the year. The stock has tumbled to a new low for the year.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT